PACB
Pacific Biosciences of California
NASDAQ: PACB · HEALTHCARE · MEDICAL DEVICES
$1.59
+8.16% today
Updated 2026-04-30
Market cap
$493.67M
P/E ratio
—
P/S ratio
3.09x
EPS (TTM)
$-1.82
Dividend yield
—
52W range
$1 – $3
Volume
5.8M
Pacific Biosciences of California (PACB) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-134.50%
ROE
-213.50%
ROA
-33.70%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2007 | $2.16M | $-21.52M | 100.00% | -1,081.41% | -994.82% |
| 2008 | $901000.00 | $-43.75M | 100.00% | -4,973.25% | -4,856.16% |
| 2009 | $135000.00 | $-87.70M | 100.00% | -65,237.04% | -64,965.19% |
| 2010 | $1.67M | $-140.17M | 100.00% | -8,377.18% | -8,373.12% |
| 2011 | $33.86M | $-109.39M | 38.49% | -324.12% | -323.03% |
| 2012 | $25.98M | $-94.47M | 3.62% | -363.08% | -363.56% |
| 2013 | $28.18M | $-79.29M | 22.78% | -275.16% | -281.37% |
| 2014 | $60.59M | $-66.16M | 38.62% | -103.73% | -109.19% |
| 2015 | $92.78M | $-31.70M | 57.61% | -31.40% | -34.16% |
| 2016 | $90.71M | $-74.38M | 48.68% | -78.54% | -81.99% |
| 2017 | $93.47M | $-92.19M | 37.08% | -96.06% | -98.63% |
| 2018 | $78.63M | $-102.56M | 31.92% | -128.44% | -130.44% |
| 2019 | $90.89M | $-84.13M | 38.04% | -110.62% | -92.57% |
| 2020 | $78.89M | $29.40M | 41.28% | -132.31% | 37.27% |
| 2021 | $130.51M | $-181.22M | 45.10% | -161.24% | -138.85% |
| 2022 | $128.30M | $-314.25M | 38.22% | -239.43% | -244.92% |
| 2023 | $200.52M | $-306.74M | 26.32% | -166.80% | -152.97% |
| 2024 | $154.01M | $-309.85M | 24.21% | -307.97% | -201.18% |
| 2025 | $160.00M | $-546.38M | 31.67% | -348.46% | -341.47% |